Tengion to Present at UBS Global Life Sciences Conference
EAST NORRITON, Pa., Sept. 14 /PRNewswire/ — Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming UBS Global Life Sciences Conference on Monday, September 20, 2010, at 8:30am EDT.
A live webcast of the presentation can be accessed under “Calendar of Events” in the Investors section of the Company’s website at www.tengion.com. A replay of the presentation will be available for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform(TM) that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit(TM), an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion’s Neo-Bladder Augment(TM) for the treatment of neurogenic bladder and is in preclinical development of its Neo-Kidney Augment(TM). Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.